solid-phase synthesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The disease was first described by the Neapolitan physician Giovanni Semmola in 1834 and Gaetano Conte in 1836. However, Duchenne muscular dystrophy is named after the French neurologist Guillaume-Benjamin-Amand Duchenne (1806–1875), who in the 1861 edition of his book Paraplégie hypertrophique de l'enfance de cause cérébrale, described and detailed the case of a boy who had this condition. A year later, he presented photos of his patient in his Album de photographies pathologiques. In 1868, he gave an account of 13 other affected children. Duchenne was the first to do a biopsy to obtain tissue from a living patient for microscopic examination.
==== 400–499 ==== Greater London, Kent and Surrey (County Boundaries) Order 1993 (S.I. 1993/400) Billing Authorities (Alteration of Requisite Calculations and Transitional Reduction Scheme) (England) Regulations 1993 (S.I. 1993/401) Staffordshire, Warwickshire and West Midlands (County Boundaries) Order 1993 (S.I. 1993/402) Education (Designated Institutions) Order 1993 (S.I. 1993/404) Organic Products (Amendment) Regulations 1993 (S.I. 1993/405) Outer Space Act 1986 (Fees) (Amendment) Regulations 1993 (S.I. 1993/406) Local Authorities (Recovery of Costs for Public Path Orders) Regulations 1993 (S.I. 1993/407) Social Security (Introduction of Disability Living Allowance) (Amendment) Regulations 1993 (S.I. 1993/408) National Health Service Trusts (Membership and Procedure) (Scotland) Amendment Regulations 1993 (S.I. 1993/412) National Health Service Trusts (Originating Capital Debt) Order 1993 (S.I. 1993/413) Lloyd's Underwriters (Tax) (1990–91) Regulations 1993 (S.I. 1993/415) Seeds (National Lists of Varieties) (Fees) (Amendment) Regulations 1993 (S.I. 1993/416) National Health Service (Optical Charges and Payments) Amendment Regulations 1993 (S.I. 1993/418) National Health Service (Dental Charges) Amendment Regulations 1993 (S.I. 1993/419) National Health Service (Charges for Drugs and Appliances) Amendment Regulations 1993 (S.I. 1993/420) Finance Act 1985 (Interest on Tax) (Prescribed Rate) Order 1993 (S.I. 1993/421) Workmen's Compensation (Supplementation) (Amendment) Scheme 1993 (S.I. 1993/422) Glasgow Caledonian University (Establishment) (Scotland) Order 1993 (S.I.
The organic compound citrulline is a non-essential α-amino acid. Its name is derived from citrullus, the Latin word for watermelon. Although named and described by gastroenterologists since the late 19th century, it was first isolated from watermelon in 1914 by Japanese researchers Yatarō Koga and Ryō Ōtake, and further codified in 1930. Citrulline has the formula H2NC(O)NH(CH2)3CH(NH2)CO2H. It is a key intermediate in the urea cycle, the pathway by which mammals excrete ammonia by converting it into urea. Citrulline is also produced as a byproduct of the enzymatic production of nitric oxide from the amino acid arginine, catalyzed by nitric oxide synthase.
== External links == "Amphetamine". European Union Drugs Agency (EUDA). CID 5826 from PubChem – Dextroamphetamine CID 32893 from PubChem – Levoamphetamine Comparative Toxicogenomics Database entry: Amphetamine Comparative Toxicogenomics Database entry: CARTPT
Sources: en.wikipedia.org
Jupiter Wagons Limited is an Indian private manufacturer of railway freight wagons, passenger coaches, wagon components, cast manganese steel crossings and castings headquartered in Kolkata, West Bengal. The company manufactures coaches for the Indian Railways and many other private companies.
Long-term exposure to outdoor and indoor air pollution adds a major environmental risk to public health in India. Particulate matter emissions from vehicles and factories are linked to a rise in chronic respiratory diseases, strokes, and cardiovascular disease, together adding an estimated 1.7 million premature deaths annually. India's early COVID-19 lockdown bought time to rapidly increase local testing and protective gear production; however, later waves of the virus overwhelmed the healthcare system, leading to severe shortages of oxygen and intensive care beds. Post-pandemic epidemiological studies estimate that cumulative excess deaths in India reached between 3.2 and 4.7 million.
Mentorship Award in Affective Science, Society for Affective Science, 2022. Ruhr Award for Philosophy and the Mind Sciences, Ruhr University Bochum, 2024 Paul D. MacLean Award for Outstanding Neuroscience Research in Psychosomatic Medicine, American Psychosomatic Society, 2024. Laureat, Pufendorf Lectures, Department of Philosophy, Lund University, 2024. William James Fellow Award, Association for Psychological Science, 2025.
== Combination of various MSI techniques and other imaging techniques == Combining various MSI techniques can be beneficial, since each particular technique has its own advantage. For example, when information regards both proteins and lipids are necessary in the same tissue section, performing DESI to analyze the lipid, followed by MALDI to obtain information about the peptide, and finalize applying a stain (haematoxylin and eosin) for medical diagnosis of the structural characteristic of the tissue. On the other side of MSI with other imaging techniques, fluorescence staining with MSI and magnetic resonance imaging (MRI) with MRI can be highlighted. Fluorescence staining can give information of the appearance of some proteins present in any process inside a tissue, while MSI may give information about the molecular changes presented in that process. Combining both techniques, multimodal picture or even 3D images of the distribution of different molecules can be generated. Recent work has demonstrated that transmission-mode MALDI-2 combined with fluorescence microscopy on the same tissue section enables single-cell-resolved MSI and precise co-registration with the optical modality. In contrast, MRI with MSI combines the continuous 3D representation of MRI image with detailed structural representation using molecular information from MSI. Even though, MSI itself can generate 3D images, the picture is just part of the reality due to the depth limitation in the analysis, while MRI provides, for example, detailed organ shape with additional anatomical information.
=== Impact on nutrition === The introduction of refrigeration allowed for the hygienic handling and storage of perishables, and as such, promoted output growth, consumption, and the availability of nutrition. The change in our method of food preservation moved us away from salts to a more manageable sodium level. The ability to move and store perishables such as meat and dairy led to a 1.7% increase in dairy consumption and overall protein intake by 1.25% annually in the US after the 1890s. People were not only consuming these perishables because it became easier for they themselves to store them, but because the innovations in refrigerated transportation and storage led to less spoilage and waste, thereby driving the prices of these products down. Refrigeration accounts for at least 5.1% of the increase in adult stature (in the US) through improved nutrition, and when the indirect effects associated with improvements in the quality of nutrients and the reduction in illness is additionally factored in, the overall impact becomes considerably larger. Recent studies have also shown a negative relationship between the number of refrigerators in a household and the rate of gastric cancer mortality.
Sources: en.wikipedia.org
== Drying defects == Drying defects are the most common form of degrade in timber, next to natural problems such as knots. There are two types of drying defects, although some defects involve both causes:
After the first two days the insurgents lost their offensive initiative, and the combined South African forces drove PLAN back across the border in a counteroffensive codenamed Operation Merlyn. Between 1 and 9 April 1989, 273 PLAN insurgents were killed in the fighting. The SADF and police suffered 23 dead. On 8 April 1989, the JMMC issued the Mount Etjo Declaration, which reiterated that the Tripartite Accord was still in effect and that South Africa, Angola, and Cuba remained committed to peace. It also ordered all PLAN insurgents remaining in Ovamboland to surrender at UNTAG-supervised assembly points. Sam Nujoma denied any incursion had taken place on 1 April, claiming that he had only ordered PLAN insurgents already inside South West Africa to begin establishing base camps. He also pointed out that SWAPO had never been a signatory to the Tripartite Accord, and therefore the cessation of hostilities as dictated by its terms was non-binding. This drew some ire from Angola, which had given guarantees to the UN that PLAN would remain north of the 16th parallel. The SADF was re-confined to its bases on 26 April, then released into Ovamboland again to verify that the insurgents had departed. By May, all but a small handful of PLAN insurgents had been relocated north of the 16th parallel under JMMC supervision, effectively ending the South African Border War. General elections under a universal franchise were held in South West Africa between 7 and 11 November 1989, returning 57% of the popular vote for SWAPO.
First generation vaccines are whole-organism vaccines – either live and weakened, or killed forms. Live, attenuated vaccines, such as smallpox and polio vaccines, are able to induce killer T-cell (TC or CTL) responses, helper T-cell (TH) responses and antibody immunity. However, attenuated forms of a pathogen can convert to a dangerous form and may cause disease in immunocompromised vaccine recipients (such as those with AIDS). While killed vaccines do not have this risk, they cannot generate specific killer T-cell responses and may not work at all for some diseases. Second generation vaccines were developed to reduce the risks from live vaccines. These are subunit vaccines, consisting of specific protein antigens (such as tetanus or diphtheria toxoid) or recombinant protein components (such as the hepatitis B surface antigen). They can generate TH and antibody responses, but not killer T cell responses. RNA vaccines and DNA vaccines are examples of third generation vaccines. In 2016 a DNA vaccine for the Zika virus began testing at the National Institutes of Health. Separately, Inovio Pharmaceuticals and GeneOne Life Science began tests of a different DNA vaccine against Zika in Miami. Manufacturing the vaccines in volume was unsolved as of 2016. Clinical trials for DNA vaccines to prevent HIV are underway. mRNA vaccines such as BNT162b2 were developed in the year 2020 with the help of Operation Warp Speed and massively deployed to combat the COVID-19 pandemic.
. The sign of the parameter will depend on the sign of the constant potential at each step, and the appropriate matrix will depend on the sign of the parameter. Because a digital waveform may be approximated as existing in only high and low states (potential sign), the stability of ions, as demonstrated by Brabeck, may be determined in as few as two or three constant potential steps. In the simple but frequent case that a full cycle of a digital waveform can be represented by two constant potential steps, the matrix representing the first potential step would be multiplied onto the matrix representing the second potential step. In the general case, the final matrix of a waveform cycle defined by n constant potential steps is:
Half-Life is a series of first-person shooter games created by Valve. The games combine shooting combat, puzzles and storytelling, and are played entirely from the first-person perspective. The original Half-Life, Valve's first product, was released in 1998 for Windows. Players control silent protagonist Gordon Freeman, a scientist working at the Black Mesa Research Facility who must survive an alien invasion caused by the facility. The use of innovative scripted sequences instead of cutscenes was influential on the first-person shooter genre, and the game inspired numerous community-developed mods, leading to the release of the multiplayer games Counter-Strike and Day of Defeat. Half-Life was followed by the expansions Opposing Force (1999), Blue Shift (2001) and Decay (2001), developed by Gearbox Software. In 2004, Valve released Half-Life 2, developed using their game engine Source. It features a more dystopian setting, stronger focus on characters and physics-based gameplay. Set twenty years after Half-Life, players control Freeman in joining a resistance to liberate humanity from an alien force known as the Combine. It was followed by the episodic sequels Episode One (2006) and Episode Two (2007). Also set in the same universe as Half-Life is the Portal series; the first game was released in 2007 followed by a sequel in 2011. Both games focus on first-person puzzle-platform gameplay using wormholes created by a portal gun.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.